Heart Failure Management Policy and Procedure Phase 1
|
|
- Eugenia Perkins
- 5 years ago
- Views:
Transcription
1 1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii Phone (808) Fax: (808) Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved by: Whitney Limm, M.D. QCIPN President & Board Chair John Houk, M.D. QCIPN Vice Chair Policy The purpose of this policy is to: I. Provide guidelines to facilitate delivery of care consistent with evidence based medical therapy for patients with heart failure AHA stage A D (see appendix A) II. Improve the quality and consistency of care by CIPN clinicians by providing education focused on evidenced based guidelines III. Differentiate treatment recommendation for heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) (see appendix B) IV. Achieve optimal guideline directed therapy for patients with heart failure by standardizing care across the continuum V. List outcome metrics to measure effectiveness of this policy Procedure I. Evidence based medical therapy per the ACC/AHA/HFSA guidelines will be used for all patient in AHA stages A D: a. Treatment in AHA stage A i. Hypertension and lipid disorders should be contributed in accordance with contemporary guidelines to lower the risk of HF. Page 1
2 1. Choice of antihypertensive therapy should follow guidelines with specific options tailored to concomitant medical problems (DM, CAD) please refer to the 2014 Evidence based guidelines for management of high blood pressure in adults (JNC 8 see ii. Management of other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. iii. Recognition of familial genetic risk obtain a 3 generation family history b. Treatment in AHA stage B (See appendix C) i. Referral to cardiology for evaluation ii. ACE inhibitors/arb s 1. In all patients with a recent or remote history of MI or ACS and/or reduced EF, ACEI should be used to prevent symptomatic HF and reduce mortality. In patients intolerant to ACEI, ARBs are appropriate unless contraindicated. iii. Evidence based beta blockers carvedilol, metoprolol succinate, bisoprolol 1. In all patients with recent or remote history of myocardial infarction, acute coronary syndrome and/or reduced left ventricular ejection fraction, evidence based beta blockers should be used to reduced mortality. 2. In all patients with a recent or remote history of MI or ACS, statins should be used to prevent symptomatic HF and cardiovascular events. 3. In patients with structural cardiac abnormalities, including LV hypertrophy, in the absence of a history of MI or ACS, blood pressure should be controlled in accordance with clinical practice guidelines. 4. Referral for cardiology evaluation 5. To prevent sudden cardiac death, placement of ICD is reasonable in patients with asymptomatic ischemic cardiomyopathy who are at least 40 days post MI, LVEF of 30% or less, are on appropriate medical therapy and have reasonable expectation of survival. 6. Class III: Harm a. Non dihydropyridine calcium channel blockers with negative inotropic effects may be harmful in asymptomatic patients with low LVEF and no symptoms of HF after MI. c. Treatment in AHA Stage C i. Referral to cardiology for concurrent management ii. Initial evaluation for new onset heart failure 1. Noninvasive Cardiac Imaging a. Patients with suspected or new onset HF, or presenting with acute decompensated HF, should undergo a chest x ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient s symptoms. Page 2
3 Page 3 b. A 2 dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with HF to assess ventricular function, size, wall thickness, wall motion and valve function. c. Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with HF who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including guideline directed medical therapy, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. d. Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo HF, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. e. Viability assessment is reasonable in select situations when planning revascularization in HF patients with CAD. f. Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. g. Magnetic resonance imaging is reasonable when assessing myocardial infiltrative process or scar burden. h. NO BENEFIT: routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should not be performed. 2. Invasive Evaluation: a. Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment. 3. Invasive hemodynamic monitoring can be useful for carefully selected patients with acute HF who have persistent symptoms despite empiric adjustment of standard therapies and: a. Whose fluid status, perfusion remains low, or is associated with symptoms, despite initial therapy b. Whose renal function is worsening with therapy c. Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy. d. Who require parenteral vasoactive agents, or e. Who may need consideration for MCS or transplantation
4 4. When ischemia may be contributing to HF, coronary arteriography is reasonable for patients eligible for revascularization. iii. Heart failure with reduced ejection fraction HFrEF 1. Non pharmacological Therapies: a. Patients with HF should receive specific education to facilitate HF selfcare. b. Exercise training is recommended as safe and effective for patients with HF who are able to participate to improve functional status. c. Sodium restriction is reasonable for patients with symptomatic HF to reduce congestive symptoms. d. Continuous positive airway pressure can be beneficial to increase LVEF and improve functional status in patients with HF and sleep apnea. e. Cardiac rehabilitation can be useful in clinically stable patients with HF to improve functional capacity, exercise duration, HRQOL, and mortality 2. Pharmacological Therapies: a. Measures listed in as Class I recommendations for patients in stages A and B are recommended where appropriate for patients in stage C. (ACEI/ARB and beta blockers) (See appendix D) b. Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (See appendix E) i. Initiate at low doses, with increase in dose until urine output increases and weight decreases generally by 0.5 to 1.0 kg daily. May need to increase frequency, add sequential nephron blockade with addition of Thiazide diuretic (metolazone, HCTZ or clorothiazine). > unresponsiveness to diuretic management attributed to poor bioavailability and gut absorption, renal impairment due to congestion and poor perfusion, dietary indiscretion or use of agents that block the effect of diuretics (NSAIDs, including COX 2 inhibitors) c. Aldosterone Receptor Antagonists are recommended in patients with NYHA class II IV HF and who have LVEF of 35% or less unless contraindicated, to reduce morbidity and mortality. i. Creatinine should be 2.5 mg/dl or less in men or 2.0 mg/dl or less in women, and potassium should be less than 5.0 meq/l. ii. Strategies to minimize hyperkalemia in patients treated with aldosterone antagonists include: 1. Initial dosing of spironolactone 12.5mg daily or eplerenone 25mg daily. May increase to 25mg spironolactone or 50mg eplerenone. Page 4
5 Page 5 2. In most cases potassium supplementation is discontinued when initiating therapy 3. Close monitoring of serum potassium is required. Check potassium levels and renal function 3 days following initiation of therapy, and at one week and monthly for at least 3 months. iii. Aldosterone receptor antagonist are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of 40% or less who develop symptoms of HF or who have a history of diabetes mellitus, unless contraindicated. d. Hydralazine with isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self described as African Americans with NYHA class III IV HFrEF receiving optimal therapy with ACEI and beta blockers, unless contraindicated. i. This combination can be used also in those patients who cannot be given ACEI or ARB because of drug intolerance, hypotension or renal insufficiency. e. Digoxin can be beneficial in patients with HFrEF unless contraindicated, to decrease hospitalizations for HF. 3. Device therapy for Stage C HFrEF a. ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients with NICM (DCM) or ischemic heart disease at least 40 days post MI with LVEF of 35% of less and NYHA class II III symptoms on chronic guideline directed management with a reasonable expectation of meaningful survival for >1 year. b. Cardiac Resynchronization Therapy is indicated for patients who have a LVEF of 35% or less, sinus rhythm, left bundle branch block with a QRS duration of 150 ms or greater, and NYHA class II IV symptoms on GDMT. (see Appendix F) c. ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post MI with LVEF of 30% or less and NYHA class I symptoms while receiving guideline directed therapy, who have a reasonable expectation of meaningful survival for <1 year. 4. Medication Therapies to avoid: a. Nutritional supplements as treatment for HF are not recommended. b. Hormonal therapies other than to correct deficiencies are not recommended.
6 c. Drugs known to adversely affect the clinical status of patients with HFrEF, i.e most antiarrhythmic drugs, most calcium channel blockers, NSAIDS, or thiazolidinediones. d. Long term use of infused positive inotropic drugs is potentially harmful for patients with HFrEF, except as palliation for patients with end stage disease who cannot be stabilized with standard medical therapy. iv. Heart failure with preserved ejection fraction HFpEF 1. Pharmacological Treatment a. Systolic and diastolic blood pressure should be controlled in patients with HFpEF in accordance with published clinical practice guidelines to prevent morbidity. b. Diuretics should be used for relief of symptoms due to volume overload in patients with HFpEF. c. Coronary revascularization is reasonable in patients with CAD in whom symptoms or demonstrable myocardial ischemia is judged to be having an adverse effect on symptomatic HFpEF despite GMDT. d. Management of AF (atrial fibrillation) according to published guidelines. e. The use of beta blocking agents, ACEI, and ARBs in patients with hypertension is reasonable to control blood pressure. d. Stage D: Advanced HF i. Referral to cardiology for management ii. Clinical events and findings useful for identifying patients with Advance HF (See Appendix G) 1. Repeat >/=2 hospitalizations or ED visits for HF in the past year 2. Progressive deterioration in renal function (e.g. rise in BUN and Cr) 3. Weight loss without other cause (e.g cardiac cachexia) 4. Intolerance to ACEI due to hypotension and or worsening renal function 5. Intolerance to beta blockers due to worsening HF or hypotension 6. Frequent systolic blood pressure <90 mmhg 7. Persistent dyspnea with dressing or bathing requiring rest 8. Inability to walk 1 bock on the level ground due to dyspnea or fatigue 9. Recent need to escalate diuretics to maintain volume status, often reaching daily furosemide equivalent dose >160 mg /d and or use of supplemental metolazone therapy. 10. Progressive decline in serum sodium, usually <133 meq/l 11. Frequent ICD shocks iii. Treatment options in stage D heart failure 1. Inotropic Support: a. Until definitive therapy (e.g. coronary revascularization, MCS, heart transplantation) or resolution of the acute precipitating problem, Page 6
7 patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end organ performance. b. Continuous intravenous inotropic support is reasonable as bridge therapy in patients with stage D HF refractory to GDMT and device therapy who are eligible for and awaiting MCS or cardiac transplantation. 2. Mechanical Circulatory Support a. MCS is beneficial in carefully selected patients with stage D HFrEF in whom definitive management (e.g. cardiac transplantation) or cardiac recovery is anticipated or planned. b. Nondurable MCS, including the use of percutaneous and extracorporeal ventricular assist device (VADs) is reasonable as a bridge to recovery or bridge to decision for carefully selected patients with HFrEF with acute profound hemodynamic compromise. c. Durable MCS is reasonable to prolong survival for carefully selected patients with stage D HFrEF. 3. Cardiac Transplantation a. Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D HF despite GDMT, device, and surgical management. 4. Palliative care a. Supportive care referral i. Increased assistance in the home for symptomatic improvement for patients with frequent hospitalizations b. Hospice referral i. End of life care e. Treatment of the acutely decompensated patient in the hospitalized setting i. Identify the precipitating cause of decompensated HF 1. Eevaluate for possible ACS with ECG and serum cardiac biomarkers. 2. Other common precipitating factors should be considered such as medication or dietary noncompliance, uncorrected high blood pressure, AF or other arrhythmias, recent addition of negative inotropic drugs (CCB s or beta blockers), initiation of drugs that increase salt retention (steroids, NSAIDs or thiazolidinediones), excessive alcohol or illicit drug use, endocrine abnormalities (DM or thyroid), concurrent infection or additional acute cardiovascular disorders (valvular disease, myopericarditis or aortic dissection). ii. Biomarkers: 1. BNP or NT probnp: useful to support clinical judgment for the diagnosis of acutely decompensated HF, especially in the setting of uncertainty for the diagnosis. 2. Measurement of BNP or NT probnp and or cardiac troponin is useful for establishing prognosis or disease severity in acutely decompensated HF. iii. Forrester Classification: Page 7
8 iv. v. Maintenance of guideline directed medical therapy during hospitalization 1. In patients with HFrEF experiencing a symptomatic exacerbation of HF requiring hospitalization during chronic treatment with guideline directed medical therapy, it is recommended that therapy be continued in the absence of hemodynamic instability or contraindications. 2. With holding of, or reduction in, beta blocker therapy should be considered only in patients hospitalized after recent initiation or increase in dose, or with marked volume overload or marginal/low cardiac output. Those with worsening renal function should be considered for temporary discontinuation of ACEI/ARB and or aldosterone antagonist. vi. Initiation of beta blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents. Beta blocker therapy should be initiated at a low dose and only in stable patients. vii. Diuretics in Hospitalized Patients: 1. Patients with HF admitted with evidence of significant fluid overload should be promptly treated with intravenous loop diuretics to reduce morbidity. 2. If patients are already receiving loop diuretic therapy, the initial intravenous dose should be equal or exceed their chronic oral daily dose and should be given in intermittent boluses or continuous infusion. Urine output and signs and symptoms of congestion should be serially assessed, and the diuretic dose should be adjusted accordingly. 3. When diuresis is inadequate to relieve symptoms, it is reasonable to intensify the diuretic regimen (double to dose or add a second thiazide diuretic). viii. Renal Replacement Therapy: Ultrafiltration 1. Ultrafiltration may be considered for patients with refractory congestion not responding to medical therapy. ix. Recommendations for discharge 1. Before hospital discharge, at the first post discharge visit and subsequent followups the following should be addressed Page 8
9 II. III. IV. a. Initiation of guideline directed therapy b. Cause of heart failure, barriers to care, limitations in support c. Assessment of volume status and blood pressure with adjustment of therapy d. Optimization of chronic oral HF therapy e. Renal function an electrolytes f. Management of comorbid conditions g. HF eduation, self care, emergency plans, adherence h. Palliative care or hospice care 2. Follow up visit scheduled within 7 14 days or telephone call within 3 days Achieve optimal guideline directed therapy for patients with heart failure by standardizing care across the continuum a. Up titrate medications in small increments to the highest tolerated target dose b. Specific sub populations (ie. elderly, chronic kidney disease) may require more frequent office visits and laboratory monitoring during medication titration c. Monitor vital signs closely with mediation titration d. Alternate adjustment of different medication classes (ie. ACE/ARB and beta blockers) e. Monitor renal function and electrolytes for changes in creatinine f. Patients may report symptoms of fatigue and weakness with dose increases. If patients are stable otherwise, these symptoms are likely transient g. Discourage sudden spontaneous discontinuation of therapy h. Carefully review all medications prior to dose adjustments i. Consider temporary adjustments in dosages with acute non cardiac illness (respiratory infection, risk of dehydration) j. Educate patients and families regarding the benefits of guideline directed medical therapy including myocardial reverse remodeling, increased survival, improved functional status and quality of life. Web based module education for review and reference by the physicians in the CIPN List outcome metrics to measure effectiveness of this policy a. Heart failure admission rates for patients in the CIPN b. Use of guideline directed therapy Page 9
10 APPENDIX A ACCF/AHA Stages and NYHA Classifications APPENDIX B DEFINITIONS OF HEART FAILURE APPENDIX C TREATMENT FOR HEART FAILURE STAGE B Page 10
11 APPENDIX D Diuretics for use in Chronic Heart Failure Stage C Page 11
12 APPENDIX E Drugs commonly used in HFrEF stage C APPENDIX F Indication for CRT therapy Page 12
13 APPENDIX G Advanced heart failure profiles References 1. Yancy CW, Jessup M, Bozkurt B, et al ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:1810. Page 13
Heart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationCitation. What is New in the 2013 ACC/AHA HF Guideline. Dimensions in Heart and Vascular Care Penn State Heart and Vascular Institute
What is New in the 2013 ACC/AHA HF Guideline Dimensions in Heart and Vascular Care Penn State Heart and Vascular nstitute Friday October 18, 2013 Barry S. Clemson, MD Associate Professor of Medicine Penn
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationOHSU HEALTH SYSTEM OFFICE OF CLINICAL INTEGRATION AND EVIDENCE-BASED PRACTICE
OHSU HEALTH SYSTEM OFFICE OF CLINICAL INTEGRATION AND EVIDENCE-BASED PRACTICE GUIDELINE FOR THE MANAGEMENT OF HEART FAILURE Background: Heart failure (HF) is a complex clinical syndrome that results from
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationChronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationAssessment and Diagnosis of Heart Failure
Assessment and Diagnosis of Heart Failure Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood and is characterized
More informationDiagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta
Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationProcess Improvement in Heart Failure Patient Care: Transitions From Door to Discharge and Beyond
Process Improvement in Heart Failure Patient Care: Transitions From Door to Discharge and Beyond Steven Sheris, M.D., FACC, FACP Chief of Cardiology Gagnon Cardiovascular Institute at Overlook Medical
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationEvaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More information2 I. Reduced EF (HFrEF)
HF Classification EF Description 2 I. Reduced EF (HFrEF) 40% 1. Referred to as systolic HF. 2. Randomized trials mainly enrolled patients with HFrEF. 3. Efficacious therapies is shown only in these patients.
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationUpdate in Congestive Hear Failure DRAGOS VESBIANU MD
Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
More informationACC Heart Failure Guidelines Slide Set
ACC Heart Failure Guidelines Slide Set Based on the 2009 Focused Update ncorporated nto the ACCF/AHA 2005 guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American
More informationDiagnosing Heart Failure in Primary Care: Differentiating Zebras from Horses
Diagnosing Heart Failure in Primary Care: Differentiating Zebras from Horses CANP March 2015 Maria Fe White, ACNP-BC Advanced Heart Disease Clinic Comprehensive Transplant Center Cedars-Sinai Medical Center
More informationWhat Is Best Care for Patients with End stage heart failure?
What Is Best Care for Patients with End stage heart failure? Jin Joo Park, MD Cardiovascular Center, Department of Internal Medicine Bundang Hospital NYHA Class Class Patient Symptoms I No limitation of
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationHEART FAILURE KEEPING YOUR PATIENT AT HOME
HEART FAILURE KEEPING YOUR PATIENT AT HOME SUZANNE FRAZIER MS, CRNP, NP-C, CHFN HEART FAILURE DISEASE MANAGEMENT COORDINATOR PENN STATE HERSHEY HEART & VASCULAR INSTITUTE IMPACT OF HEART FAILURE In 2010,
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationHeart.org/HFGuidelinesToolkit
2017 /H/HFS Focused Update of the 2013 F/H 6.3.1 Biomarkers for Prevention: Recommendation OR LOE Recommendation a For patients at risk of developing HF, natriuretic peptide biomarker-based screening followed
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationThe CCS Heart Failure Companion: Bridging Guidelines to your Practice
The CCS Heart Failure Companion: Bridging Guidelines to your Practice Looking for practical answers concerning optimal heart failure care? The CCS Heart Failure Guidelines Companion can help. The Canadian
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationOutline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center Scientific
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationBackground: Patient Adherence Challenges/Barriers
This Nurse Tip Sheet was developed by AAHFN as resource in facilitating patient education. It provides additional information so that the Nurse can supplement patient teaching with the corresponding Patient
More informationTri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM
Tri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM Faculty Disclosure Banner Baywood Medical Center -Chief of Staff FIFTH ANNUAL SYMPOSIUM NYHA class III-IV symptoms Clinical signs of fluid retention
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationCase 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?
Case 1 A primary care colleague inquires what to do with a patient (HFrEF in NSR) who has a digoxin level of 2.8ng/ml. Level was obtained at 10am, patient takes all medications at one time upon arising
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationBalanced information for better care. Heart failure: Managing risk and improving patient outcomes
Balanced information for better care Heart failure: Managing risk and improving patient outcomes Heart failure increases hospitalization Heart failure is the most common medical reason for hospitalization
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationHeart failure for syndicate
Heart failure for syndicate By M.Wafaie Aboleineen,MD,FACC ESC Guidelines for the diagnosis and treatment of heart failure Part I 1 4 2 Common ECG abnormalities in HF 3 Common CXR abnormalities in HF Common
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationChronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)
Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update) NICE guideline Apendix C The algorithms Draft for consultation, January 2010 Chronic
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationAbby Woods, DNP, FNP Southern Illinois Healthcare Supportive Care Program END OF LIFE ISSUES IN THE CARE OF CARDIAC PATIENTS
Abby Woods, DNP, FNP Southern Illinois Healthcare Supportive Care Program END OF LIFE ISSUES IN THE CARE OF CARDIAC PATIENTS Objectives Describe a team approach in the setting of critical illness Differentiate
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationManagement of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU
Management of acute decompensated heart failure and cardiogenic shock Arintaya Phrommintikul Department of Medicine CMU Acute heart failure: spectrum Case 64 y/o M with Hx of non-ischemic DCM (LVEF=25-30%)
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationDisclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018
Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More information